ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer
The Institute of Cancer Research, London, UK, has welcomed the announcement by NICE that it…
Browsing: Abiraterone
ESMO 2020: Two-pronged attack using new targeted drug could treat ‘addicted’ prostate cancers
An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of…
Urgent call to kick-start life-saving cancer research so cancer patients don’t get left behind
The Institute of Cancer Research, London, UK, has launched a major fundraising appeal as it…
The Oncology Journal Club Episode 6: GI Update with Fotios Loupakis and much more…
The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode…
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer
The Institute of Cancer Research, London, has expressed disappointment at the decision by NICE not to recommend…
Prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common…
Abiraterone May Be More Effective in Black Men With Advanced Prostate Cancer Than in White Men
In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response…
New blood test predicts who will benefit from targeted prostate cancer treatments
A new blood test could predict which men with advanced prostate cancer will respond to…
Prostate cancer drug combination shows promise in early trial
A combination of two drugs for prostate cancer is safe and shows signs of effectiveness…
Non-profit drug development could cut cost of cancer medicines
Universities should work with new forms of commercial partner to take their own cancer drugs…